Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum

被引:43
作者
Baracat, JS [1 ]
Teixeira, CE [1 ]
Okuyama, CE [1 ]
Priviero, FBM [1 ]
Faro, R [1 ]
Antunes, E [1 ]
De Nucci, G [1 ]
机构
[1] Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, BR-13081970 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
corpus cavernosum; BAY; 41-2272; soluble guanylyl cyclase; sildenafil; nitric oxide (NO);
D O I
10.1016/j.ejphar.2003.08.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
5-Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 41-2272) is a potent soluble guanylyl cyclase stimulator in a nitric oxide (NO)-independent manner. The relaxant effect of BAY 41-2272 was investigated in rabbit and human corpus cavernosum in vitro. BAY 41-2272 (0.01 - 10 muM) relaxed both rabbit (pEC(50) = 6.82 +/- 0.06) and human (pEC(50) = 6.12 +/- 0.10) precontracted cavemosal strips. The guanylyl cyclase inhibitor (ODQ, 10 muM) caused significant rightward shifts in the concentration-response curves for BAY 41-2272 in rabbit (4.7-fold) and human (2.3-fold) tissues. The NO synthesis inhibitor (N-nitro-(L)-arginine methyl ester ((L)-NAME), 100 muM) also produced similar rightward shifts, revealing that BAY 41-2272 acts synergistically with endogenous NO to elicit its relaxant effect. The results also indicate that ODQ is selective for the NO-stimulated enzyme, since relaxations evoked by BAY 4 1 2272 were only partly attenuated by ODQ. The present study shows that both BAY 41-2272 and sildenafil evoke relaxations independent of inhibition of haem in soluble guanylate cyclase. Moreover, there is no synergistic effect of the two compounds in corpus cavernosum. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 36 条
[1]   PHYSIOLOGY OF PENILE ERECTION [J].
ANDERSSON, KE ;
WAGNER, G .
PHYSIOLOGICAL REVIEWS, 1995, 75 (01) :191-236
[2]  
Andersson KE, 2001, PHARMACOL REV, V53, P417
[3]   BAY 41-2272: A stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo [J].
Bischoff, E ;
Schramm, M ;
Straub, A ;
Feurer, A ;
Stasch, JP .
UROLOGY, 2003, 61 (02) :464-467
[4]   Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4) [J].
Bivalacqua, TJ ;
Champion, HC ;
Rajasekaran, M ;
Sikka, SC ;
Kadowitz, PJ ;
Doherty, PC ;
Hellstrom, WJG .
JOURNAL OF UROLOGY, 1999, 162 (05) :1848-1855
[5]   Pharmacotherapy for erectile dysfunction [J].
Bivalacque, TJ ;
Champion, HC ;
Hellstrom, WJG ;
Kadowitz, PJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (12) :484-489
[6]  
Burette A, 2001, J COMP NEUROL, V431, P1, DOI 10.1002/1096-9861(20010226)431:1<1::AID-CNE1051>3.0.CO
[7]  
2-E
[8]   Characterization of nitroglycerine-induced relaxation in human corpus cavernosum smooth muscle: Implications to erectile physiology and dysfunction [J].
Christ, GJ ;
Him, DC ;
Taub, HC ;
Gondre, CM ;
Melman, A .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (12) :1714-1726
[9]   Cyclic GMP phosphodiesterase-5: Target of sildenafil [J].
Corbin, JD ;
Francis, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) :13729-13732
[10]   Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction [J].
Corbin, JD ;
Francis, SH ;
Webb, DJ .
UROLOGY, 2002, 60 (2B) :4-11